Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Biogen Idec
Woman and Man Max 99 years
Biogen Idec Inc
Update Il y a 4 ans
Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis
The primary objective of this study is to determine the efficacy of three dose levels of BG00012 on brain lesion activity as measured by MRI in subjects with relapsing-remitting MS when compared to pl...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Biogen Idec
Update Il y a 4 ans
BIOGEN IDEC 152CL202 : Essai de phase 2 randomisé évaluant l’efficacité et la tolérance d'un traitement par fludarabine, cyclophosphamide et rituximab associé ou non à du lumiliximab, en traitement de première ligne, chez des patients ayant une leucémie lymphocytaire chronique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A phase 2, randomized, open-label study to evaluate ECG results and pharmacokinetic parameters for fludarabine, cyclophosphamide, and rituximab (FCR) in combination with lumiliximab versus FCR alone i...
Country
France
organs
Leucémies chroniques
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
221AD302 Phase 3 Study of Aducanumab in Early Alzheimer's Disease
Placebo-controlled period: To evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the CDR-SB score as compared with placebo i...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Italia S.r.l
Update Il y a 4 ans
Experimental clinical trial regarding relapsing-remitTing Multiple Sclerosis newly diagnosed patients, not yet treated for the evaluation of the onset, the efficacy and speed of action of the treatment with BG00012 Studio clinico di tipo sperimentale in pazienti affetti da sclerosi multipla recidivante-remittente di nuova diagnosi, non ancora trattati per valutare l'esordio, l'efficacia e la velocità di azione del trattamento con BG00012
The primary objective of the study is to assess the early efficacy of treatment with BG00012 240 mg BID in the brain of newly diagnosed and naive-to-treatment patients with RRMS. L’obiettivo pri...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Biogen Idec Research Ltd
Update Il y a 4 ans
A clinical study involving previously untreated patients with haemophilia B to look at how safe an experimental replacement factor IX protein (known as rFIXFc) is to take and how well it works to prevent and stop bleeds
The primary objective of the study is to evaluate the safety of rFIXFc in previously untreated subjects with severe hemophilia B.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects with Relapsing Remitting Multiple Sclerosis Studio di fase I, multicentrico, in aperto, a braccio singolo, a dose multipla per valutare la farmacocinetica e la farmacodinamica di natalizumab in soggetti pediatrici con sclerosi multipla recidivante remittente
The primary objective of the study is to determine the PK profile of multiple doses of natalizumab in pediatric subjects with RRMS. L’obiettivo primario dello studio è di determinare il profilo ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Biogen Idec Inc. (USA)
Update Il y a 4 ans
Phase IIa trial of interferon-beta-1a (Avonex) in patients with rheumatoid arthritis
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Research Limited
Update Il y a 4 ans
Natalizumab (BG00002) as an Efficacy Switch in Subjects with Relapsing Multiple Sclerosis (MS) after Failure on Other Therapies
The primary objective of the study is to determine the efficacy of Tysabri in subjects with relapsing forms of MS who have failed Gilenya or BRACET as measured by the proportion of subjects with no ev...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Ltd
Update Il y a 4 ans
Multicentre, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects with Relapsing-Remitting Multiple Sclerosis
Primary objective: To determine whether DAC HYP, when compared to placebo, is effective in reducing the rate of relapse between baseline and week 52
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Biogen Idec Limited
Update Il y a 4 ans
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of BG00012 when given with Methotrexate to Subjects with Active Rheumatoid Arthritis who have had an Inadequate Response to Coventional Disease-Modifying Anti-rheumatic Drug Therapy
The primary objective of this study is to evaluate the clinical efficacy of BG00012 with MTX in subjects with active RA who have had an inadequate response to DMARD therapy.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
2
3
4
5
6
7
8
9
Next